Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Raw Materials (2020 - 2025)

IceCure Medical (ICCM) has disclosed Raw Materials for 6 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 28.2% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 28.2% year-over-year, with the annual reading at $1.8 million for FY2025, 28.2% up from the prior year.
  • Raw Materials for Q4 2025 was $1.8 million at IceCure Medical, up from $1.4 million in the prior quarter.
  • The five-year high for Raw Materials was $1.8 million in Q4 2025, with the low at $704000.0 in Q4 2021.
  • Average Raw Materials over 5 years is $1.4 million, with a median of $1.4 million recorded in 2024.
  • The sharpest move saw Raw Materials surged 122.44% in 2022, then dropped 11.17% in 2023.
  • Over 5 years, Raw Materials stood at $704000.0 in 2021, then surged by 122.44% to $1.6 million in 2022, then decreased by 11.17% to $1.4 million in 2023, then increased by 1.22% to $1.4 million in 2024, then grew by 28.2% to $1.8 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $1.8 million, $1.4 million, and $1.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.